These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1761450)

  • 1. Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients.
    Li SC; Bowes G; Ioannides-Demos LL; Spicer WJ; Hooper RE; Spelman DW; Tong N; McLean AJ
    J Antimicrob Chemother; 1991 Oct; 28(4):561-8. PubMed ID: 1761450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
    Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
    Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
    Hennig S; Holthouse F; Staatz CE
    Clin Pharmacokinet; 2015 Apr; 54(4):409-21. PubMed ID: 25403847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
    Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
    Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment.
    Horrevorts AM; de Witte J; Degener JE; Dzoljic-Danilovic G; Hop WC; Driessen O; Michel MF; Kerrebijn KF
    Chest; 1987 Nov; 92(5):844-8. PubMed ID: 3665599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of high-dose tobramycin-carbenicillin therapy in pseudomonal infections in cystic fibrosis.
    Fraser GL; Valenti AJ; Grimes GR; Corbin RP
    Drug Intell Clin Pharm; 1985 Oct; 19(10):757-61. PubMed ID: 4053983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring.
    Bartel K; Habash T; Lugauer S; Bärmeier H; Böwing B; Unsal M; Schoerner C; Heininger U
    Infection; 1999; 27(4-5):268-71. PubMed ID: 10885841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis.
    Staubes BA; Metzger NL; Walker SD; Peasah SK
    Pharmacotherapy; 2016 Jun; 36(6):623-30. PubMed ID: 27138730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis.
    Jackson MA; Kusmiesz H; Shelton S; Prestidge C; Kramer RI; Nelson JD
    Pediatr Infect Dis; 1986; 5(4):440-3. PubMed ID: 3725655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.
    Barras MA; Serisier D; Hennig S; Jess K; Norris RL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6698-6702. PubMed ID: 27572411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.
    McCrae WM; Raeburn JA; Hanson EJ
    J Infect Dis; 1976 Aug; 134 Suppl():S191-3. PubMed ID: 972281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
    Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
    J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.
    Pedersen SS; Jensen T; Osterhammel D; Osterhammel P
    Antimicrob Agents Chemother; 1987 Apr; 31(4):594-9. PubMed ID: 3606063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis.
    Touw DJ; Vinks AA; Heijerman HG; Hermans J; Bakker W
    Ther Drug Monit; 1994 Apr; 16(2):125-31. PubMed ID: 8009558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
    van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
    J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.